Seagen Inc.

Matthew R Levengood

Vivian Trang

Michael Feldhaus

Lori Westendorf

Shyra Gardai

Christopher Carosino

Che Leung-Law

Peter Senter

Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

CD47 antibodies and uses thereof for treating cancer

The present disclosure provides, inter alia, multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units, that are constructed in a site-specific matter via 'orthogonal' deprotection and drug loading. Also provided are, Protected Linking Assembly Units, which allow for 'orthogonal' deprotection and construction of MD-ADCs and LA Units of the present disclosure.

Multi-drug antibody drug conjugates

The invention provides bivalent antibodies including two light and heavy chain pairs. The N-termini of one or both light and heavy chain pairs are linked via linkers comprising a protease cleavage site to coiled-coil forming peptides that associate to form a coiled coil reducing binding affinity of at least one light-heavy chain pair to a target.

Bivalent antibodies masked by coiled coils

Growing community of inventors

Bothell, WA, United States of America

Matthew R Levengood